<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112020</url>
  </required_header>
  <id_info>
    <org_study_id>S10-0088</org_study_id>
    <nct_id>NCT01112020</nct_id>
  </id_info>
  <brief_title>Components of Chlorhexidine Gluconate Dressing</brief_title>
  <official_title>Components &amp; Tolerability of Chlorhexidine Gluconate Dressing Patch Compared to BioPatch &amp; Tegaderm Chlorhexidine Gluconate Securement Dressing After Application to Healthy Subjects Over a 7-day Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareFusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareFusion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the contents of a chlorhexidine-containing dressing
      after use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the chemical composition of the CHG (2% CHG) Catheter Dressing Patch as
      compared to Biopatch Protective Disk with CHG, and Tegaderm IV (intravenous) Securement
      Dressing over a wear period of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chlorhexidine gluconate (CHG) level</measure>
    <time_frame>1 week</time_frame>
    <description>CHG level in dressing after 7 days exposure to CHG-containing test articles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parachloroaniline (PCA) level</measure>
    <time_frame>7 days</time_frame>
    <description>PCA level in dressing after 7 days exposure to CHG-containing test articles</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CHG Catheter Dressing Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biopatch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biopatch Protective Disk with CHG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegaderm CHG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tegaderm CHG IV Securement Dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHG Catheter Dressing Patch</intervention_name>
    <description>2% CHG dressing applied to 7 sites</description>
    <arm_group_label>CHG Catheter Dressing Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biopatch</intervention_name>
    <description>Biopatch applied to 7 sites</description>
    <arm_group_label>Biopatch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tegaderm CHG</intervention_name>
    <description>Tegaderm CHG IV Securement Dressing applied to 7 sites</description>
    <arm_group_label>Tegaderm CHG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read, review and sign the Informed Consent

          -  Willing to shower using the same soap/cleansers from the Screening Visit through the
             end of the study

          -  Use study-approved contraceptive methods

        Exclusion Criteria:

          -  Participation in an investigational study within 28 days prior to dosing.

          -  Clinically significant illness within 28 days prior to dosing.

          -  History of allergic responses to chlorhexidine, chlorhexidine-containing products,
             glycerol, adhesives, latex

          -  History of clinically significant skin disorders

          -  History of Type I diabetes mellitus, insulin-dependent diabetes mellitus(IDDM)

          -  History of significant dermatologic cancers (melanoma, squamous)

          -  Known history of immunologic disorders

          -  Use immunosuppressive or other proscribed medications

          -  Use of skin products at the application site

          -  Significant history of allergies to soaps, lotions, emollients, ointments, creams

          -  History of drug or alcohol addiction within the past year

          -  Pregnant, lactating, breast-feeding, or intends to become pregnant during the course
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Vargas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlorhexidine digluconate (CHG)</keyword>
  <keyword>Biopatch Protective Disk</keyword>
  <keyword>Tegaderm CHG IV (intravenous) Securement Dressing</keyword>
  <keyword>parachloroaniline (PCA)</keyword>
  <keyword>No condition being studied.</keyword>
  <keyword>Assessing components of CHG-containing dressings after use.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

